{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.16","value":"70.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.80","value":"68.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"}],"units":"Participants"}],"title":"Cycle 3 Day 1: Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.49","value":"68.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Cycle 4 Day 1: Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.52","value":"64.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Cycle 5 Day 1: Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.58","value":"61.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"Cycle 6 Day 1: Dacomitinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.55","value":"13.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"}],"units":"Participants"}],"title":"Cycle 2 Day 1: PF-05199265"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.10","value":"14.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"}],"units":"Participants"}],"title":"Cycle 3 Day 1: PF-05199265"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"13.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Cycle 4 Day 1: PF-05199265"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.69","value":"12.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Cycle 5 Day 1: PF-05199265"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.52","value":"13.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"title":"Cycle 6 Day 1: PF-05199265"}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"description":"Trough plasma concentration was defined as the measured concentration at the end of a dosing interval at steady state (taken directly before next administration).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"}],"paramType":"MEAN","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least one measured plasma concentration and were dose-compliant. Dose-compliant participants were those who received 45 mg dacomitinib daily without interruptions or dose reductions for at least 14 days prior to the day of data collection. Here, 'Number Analyzed' = participants evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 2, 3, 4, 5 and 6","title":"Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265","type":"SECONDARY","unitOfMeasure":"ng/mL"}